Novelion Therapeutics (STU:QLTA) EV-to-EBIT : -4.42 (As of May. 22, 2024)

Novelion Therapeutics EV-to-EBIT Chart

Novelion Therapeutics Annual Data
	Trend	Dec09	Dec10	Dec11	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18
EV-to-EBIT		Get a 7-Day Free Trial					0.13	1.45	-7.43	-3.10	-6.66

Novelion Therapeutics Quarterly Data
	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19
EV-to-EBIT	Get a 7-Day Free Trial															-3.46	-3.48	-5.27	-6.66	-7.80

Competitive Comparison of Novelion Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Novelion Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novelion Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novelion Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Novelion Therapeutics's EV-to-EBIT falls into.

Novelion Therapeutics EV-to-EBIT Calculation

Novelion Therapeutics's EV-to-EBIT for today is calculated as:

Novelion Therapeutics's current Enterprise Value is €162.7 Mil.
Novelion Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was €-36.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novelion Therapeutics  (STU:QLTA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Novelion Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2019 is calculated as:

Novelion Therapeutics's Enterprise Value for the quarter that ended in Mar. 2019 was €0.0 Mil.
Novelion Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was €-36.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novelion Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Novelion Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Novelion Therapeutics (STU:QLTA) Business Description